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ABSTRACT 
Purpose: As preemptive pharmacogenetics expands in the academic healthcare setting, further 
study is needed to assess the views of additional stakeholders in the marketplace on this 
technology and the barriers and facilitators to their uptake. The purpose of this study is to 
investigate the perspectives and opinions about coverage policies for preemptive 
pharmacogenetic testing of third-party payers. 
Methods: A qualitative study utilizing a blended inductive and directed approach was 
conducted. A screener survey determined interview eligibility as well as demographic data. 
Semi-structured interviews were conducted with payers from organizations of varying structure 
and beneficiary populations. Meaning units and codes were used for each interview and 
aggregated to identify the subthemes and major themes.  
Results: A total of 14 payers were interviewed, covering 122,000,000 million lives, or almost 
40% of the U.S. population. Positive and negative opinions were noted. Most positive opinions 
were prefaced with a position that pharmacogenetics held great potential for the healthcare 
system, but that full implementation was several years away. The work of the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenomics Research 
Network (PGRN) was viewed favorably. However, this would not drive policy decisions. 
Negative opinions came from a concern of the lack of data that would make these tests 
actionable for a payer from a policy development point of view. Concerns about the cost of 
testing large numbers of people was mentioned frequently, as well as the inability to predict 
iii 
 
when a patient or physician would use the data from a test or potential cost savings from the 
technology. 
Discussion: Preemptive pharmacogenetic testing remains a cautious pursuit for many payers. 
Lacking clinical outcomes data, the inability to evaluate the economic benefits from testing, and 
high costs are a few central concerns. Real-world implementations from academic institutions 
and the work of CPIC were seen as promising endeavors. The research community of 
pharmacogenetic advocates should review this study and focus their efforts on providing the data 
needed to guide informed policy decision making with regard to pharmacogenetic testing.
iv 
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1. INTRODUCTION 
 Clinical pharmacogenetics has the potential to be one of the next great innovations in 
precision medicine and tailoring of patient treatments. The phrase, "the right drug, at the right 
dose, the first time", has become synonymous with pharmacogenetic testing and the 
improvements that it may possibly bring. This hope has been met with significant barriers to 
implementation, due to claims by some of insufficient clinical evidence and results which have 
not been integrated into the decision making process of clinicians.
1
  
 The most common form of pharmacogenetic testing is the point-of-care or "reactive" 
testing method and it can occur in two forms: the testing of somatically acquired genomic 
variation and the testing of germline genomic variation. A commonality between the forms is 
that the patient is diagnosed with a condition and subsequently given the test or the companion 
diagnostic to determine the appropriate course of treatment. The difference in the reactive form 
comes from the type of reactive test, the genotyping of the patient or of a tumor. The former 
corresponds to the germline genomic variation, and the latter to the somatically acquired 
genomic variation. The genotyping of the patient will identify a specific gene variation that 
impacts human drug metabolism, transport, distribution, and excretion for certain medications.  
Genotyping of the tumor has been used to guide decisions on the type of anticancer agent 
to use based on the likelihood of a response, and to develop novel therapies that target specific 
genetic mutations within the tumor. Inherited genome variations in cancer can also influence 
response. The desired outcome for genotyping the patient or the tumor is to characterize the
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corresponding drug response phenotypes such as efficacy, toxicity, or desired pharmacologic 
effects. This has become the more difficult challenge for pharmacogenetics as well translating 
these discoveries into clinical practice.
 2
  
 The development of a newer form of testing for germline genomic variations, preemptive 
pharmacogenetic testing, takes a broader approach to genotyping the patient by assaying 
thousands of genetic variants with a single test with the results being entered into a patient's 
electronic health record for future reference. Current adoption of preemptive pharmacogenetic 
testing has been limited to a few consortiums composed mostly of academic medical centers. 
These include the Pharmacogenetics Research Network (PGRN), the Electronic Medical Records 
and Genomics Network (eMERGE), and Implementing GeNomics in Practice (IGNITE).The 
costs of implementing the technology, to this point, has fallen predominantly on the individual 
institution through the pursuit of grants and internal funding. Many of these programs are 
supported by the National Institutes of Health (NIH) and the National Human Genome Research 
Institue (NHGRI). This has limited the spread of this technology to only a few locations and 
clinical settings.  
These tests have struggled to gain widespread coverage among third-party payers, 
although the testing of somatically acquired genomic variation has enjoyed slightly more success 
in that regard.
3
 Historically, payers have identified the need for more data on clinical outcomes 
and prospective comparative-effectiveness studies, ideally randomized-controlled trials, as well 
as evidence that clinical utility exists to consider coverage for these types of tests.
4,5
 The clinical 
utility of these tests has become a more important consideration for payers, as they pursue the 
real-world applicability of medical innovations.
4,6 
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 The primary objective of this research is to investigate the perspectives and opinions 
about coverage and reimbursement policies for preemptive pharmacogenetic testing from third-
party payers through a series of in-depth interviews. 
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2. BACKGROUND 
 To many health care leaders, an emphasis on value has been the driving force behind 
decision making in recent years. Value is a relationship between desired outcomes and the cost 
needed to achieve those outcomes.
7
 Precision or personalized medicine is thought by many 
health care leaders to be a way to increase value by leaving the population-based treatment 
approach behind and advancing to a patient-centered model of care.
7
 The Personalized Medicine 
Special Interest group of the International Society of Pharmacoeconomics and Outcomes 
Research (ISPOR) defines personalized medicine as follows: the use of genetic or other 
biomarker information to improve safety, effectiveness, and health outcomes of patients via more 
efficiently targeted risk stratification, prevention, and tailored medication and treatment-
management approaches.
8
 The NIH has encouraged the adoption of the term "precision" over 
"personalized" when discussing pharmacogenetics as to prevent the misinterpretation that a 
treatment or prevention has been developed for an individual.
9
 The term precision medicine is 
the broadest of all terms and also seeks to include non-genomic factors such as lifestyle and 
environment.  
 
Overview of Pharmacogenetic Testing 
It is important to note that the focus of pharmacogenetics must be distinguished from other areas 
of clinical genomics that focus on the identification or risk of genetic or chromosomal 
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conditions. Pharmacogenetics works by determining how germline or somatic mutations affect 
the metabolic pathways that determine an individual's response to a drug.
10
 A germline mutation 
is a detectable or heritable variation in the lineage of germ cells, while a somatic mutation is a 
genetic alteration that is acquired by a cell and then passed along during cell division. Somatic 
mutations, with respect to pharmacogenetics, are mostly involved in the detection of genetic 
variants in the cells of tumors and related drug response. Pharmacogenetic testing does not focus 
on the identification of disease risk, and there is little importance that can be gleamed from 
assessing the genomic variants of an individual and this relationship. In so doing this test avoids 
some of the ethical issues surrounding other types of genetic testing.
1
    
 The discovery of the hepatic cytochrome P450 in 1977 was one of the most important 
discoveries for the advancement of pharmacogenetics.
11
 The CYP450 gene superfamily is 
involved in the metabolism of about 75% of commonly prescribed drugs. The polymorphic drug 
metabolism enzymes associated with CYP450 genes are prone to variations in the number of 
copies, including full gene deletion or duplication, which ultimately effects how a drug would be 
metabolized within a patient’s body affecting the safety and efficacy with some patients. The 
genotypes of these enzymes are typically categorized as five metabolism phenotypes: ultrarapid, 
rapid, normal, intermediate, and poor.
11 
Take the CYP2D6 enzyme, a member of the CYP450 
gene superfamily, for example, a patient that presents with multiple copies of this may be 
classified as a rapid metabolizer of certain medications and will therefore require an increased 
dose. Conversely, for a patient lacking functional CYP2D6 enzymes the normal dose would 
exceed the therapeutic target, potentially resulting in an adverse drug reaction (ADR).
 
ADRs are 
a significant safety risk, causing increased morbidity and associated high costs, as well as being 
one of the most common causes of death.
12 
Many patient factors may contribute to an increased 
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risk of an ADR, but somewhere between 10-20% of ADRs are due to genetic factors.
13 
By 
determining the mechanisms and effects of a genomic variation on drug response these kinds of 
ADRs can be prevented.  
 
Benefits of Pharmacogenetic Testing 
Pharmacogenetic testing in clinical practice may benefit the patient in several ways. The 
use of a pharmacogenetic test can enable more patient-centered care by involving the patient in 
the decision making process.
14 
This involvement in the treatment decisions is likely to be 
associated with a better patient-physician relationship and increased trust, leading to the potential 
for greater adherence to the medication therapy.
15
 They may perceive the therapy is more 
beneficial or has less risks, given the pharmacogenetic test results have informed the treatment 
choice. Also, patients who participate in pharmacogenetic testing may be psychologically 
affected in a manner which encourages a more active role in their own health management. 
Because the results of the pharmacogenetic tests inform the selection and dosing of drug therapy, 
these tests are likely to address patient concerns about therapy. Some patients may perceive little 
or no need for a therapy or doubt its effectiveness. If the pharmacogenetic test results indicate 
that this therapy is likely to work in this patient, the patient may be more willing to adhere to the 
medication therapy.
 14
  
Similarly, using pharmacogenetic test results is a proactive medication safety strategy 
that can provide information to decrease the risk of adverse drug reactions (ADRs) and improve 
drug selection. Recall the example of the patient with multiple copies or a deletion of a CYP2D6 
enzyme in the CYP450 gene, consequently requiring increased or decreased drug dosing, 
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respectively, to offset the change in metabolization. The identification of genetic factors that may 
predispose a patient to an ADR can be helpful in preventing its occurrence.
16
 Pharmacogenetic 
testing will also help select effective therapy initially. A landmark psychiatric clinical trial 
(STAR-D), completed in 2006 for patients with major depressive disorder, showed that only one-
third of patients achieved remission from their initial treatment, meaning that patients generally 
need to try multiple medications.
17
 The burden of switching to different therapies to find an 
effective treatment can be costly for patients and the entire health care system as well as slow the 
treatment of their condition.
18
 The problem is compounded depending on the number of 
medication changes, which are required, and the time necessary to find the correct therapeutic 
approach. Furthermore, early detection and treatment with an appropriate drug lessen the effects 
of the disease on the body, arriving at better clinical outcomes for the patient.
14 
The concomitant 
research on the economic utility for many pharmacogenetic tests combined with clinical 
evidence will be a determinant of potential value to the health system.  
 A study from 2014 identified 59 cost-utility analyses of precision medicine tests between 
the years 1998 and 2011. The findings from the 2014 study revealed that most studies (72%) 
showed testing provided better health at higher cost, while 20% showed cost saving.
19
 Cost 
saving in this case means that a negative incremental cost effectiveness ratio (ICER) resulted 
from the analysis. Roughly half of the studies that provided better health at higher cost fell under 
the $50,000/QALY threshold while 80% of the studies fell under the $100,000/QALY threshold. 
The former $50,000/QALY threshold is used as a decision tool by the National Institute of 
Health and Clinical Excellence in England (NICE) and the $100,000/QALY threshold is used 
unofficially in the United States.
19,20
 It is important to note however that there are many factors 
which can influence the outcomes for the economic value of pharmcogenetic testing, including 
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test cost, treatment cost, the nature of the indication, treatment benefits with and without the test, 
and the prevalence of the pharmacogenetic variant.
20
  
In a recent study, Brixner et al. used an observational study design of elderly patients 
(≥65 years old) with a prescription or dose change of at least one of sixty-one oral drugs within 
120 days of enrollment that were on 3 or more total medications.
21
 This prospective group was 
propensity score matched with a retrospective cohort from a claims database. The prospective 
group was given a CYP 450 pharmacogenetic test and providers used a clinical decision support 
tool including this new information on patients for a four-month period to measure healthcare 
resource utilization. Those patients in the tested group showed a significantly lower rate in 
hospitalizations, 9.8% vs. 16.1%, p<0.027, and in emergency department visits, 4.4% vs. 15.4%, 
p<0.0002. The rate of healthcare resources utilization was higher in the tested group, most likely 
due to more outpatient visits, but the potential cost savings were estimated at $218 per patient in 
the tested group.  
The economics of health care and drug discovery can also benefit from the expansion of 
pharmacogenetics in the industry. Deverka et al. explain that developing products through 
pharmacogenetics can reduce the cost of drug development programs by allowing for smaller 
and less expensive clinical trials, reducing the development time for a product, and increasing 
FDA approval rates.
18
 Moreover, pharmacogenetics could be used to "rescue" certain drugs that 
may have never made it to market because of severe ADRs. For example, the drug could be 
made available to the cohort of patients who test negative for the genetic variant leading to the 
ADR. However, because pharmaceutical companies will be catering to a much more stratified 
population, incentives such as longer patent life and beneficial pricing contracts will be essential 
to encourage this type of drug discovery.  
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Types of pharmacogenetic testing 
 There exist two broad groups of pharmacogenetic testing: somatic and germline testing, 
the latter can be subdivided into reactive/point-of-care testing and preemptive testing. The 
following section provides a brief discussion of each of these types.  
 
Reactive-Somatic/companion diagnostic tests 
 As pharmacogenetic testing has progressed so has the availability of more advanced types 
of testing. This has led to the development of what is commonly referred to as “companion 
diagnostic tests”. These tests are typically developed and tested concurrently with the drug in the 
early phases of clinical trials.
5
 The goal of these companion tests is to genotype the tumor and 
break down the complexity, thereby identifying potential tailored treatments for specific types of 
patients.
4
 It is suggested that the use of the companion diagnostics will facilitate selection of 
appropriate treatment and lead to better medication-related outcomes. Additionally, it may 
prevent money being spent on expensive, advanced biologic drug therapy for patients with 
tumors not likely to respond to the drug therapy. Drug development in oncology products has 
been an active area of research for pharmacogenetics, particularly in lung and breast cancer. 
Currently, the United States Federal Drug Administration (FDA) requires pharmacogenetic 
testing for use of trastuzumab, cetuximab, and panitumumab.  
 Some companion diagnostics may be co-developed with a drug and by the manufacturer 
of that drug, while independent companies may develop tests for drugs that are currently used in 
medical practice. Experts see the development of post hoc companion diagnostics growing 
moderately over the coming years.
5
 The acceptance and use of germline mutation diagnostic 
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testing has been noticeably less than that of its somatic counterparts used in the treatment of 
cancer. A major cause of this discrepancy may be the impact that testing in cancer products has 
on the reduction in utilizing expensive medications in patients where the drug therapy is not 
likely to work.  
 
Reactive-Germline mutation testing 
 Germline mutation testing can be divided into two main groups: reactive or point-of-care 
and preemptive pharmacogenetic testing. Reactive pharmacogenetic testing is the one-at-a-time 
approach where the test is typically ordered at the point of care when initiating a treatment.
22 
Support for the use of reactive pharmacogenetic testing comes from the assumption that there is 
an increased likelihood the results will be applied by the clinician because the prescribing 
decision will be inexorably linked to the results of the pharmacogenetic test.
 
Furthermore, the 
gene-by-gene basis of testing allows for the testing to be done on those patients who have been 
diagnosed with a specified condition.
1
 This can have both advantages and disadvantages. One 
advantage is that unnecessary testing is avoided and the subsequent cost associated by offering 
the pharmacogenetic test only to those with a specific indication.  
A budget impact analysis of CYP2C19 genotyping in patients receiving dual antiplatelet 
therapy including clopidogrel, which is known to incur serious ADRs for poor and intermediate 
metabolizers, was recently conducted.
23
 The model assumed that patients had been diagnosed 
with acute coronary syndrome (ACS) and would have received a percutaneous coronary 
intervention (PCI). The budget impact was considered for three clinical scenarios: no patients 
received CYP2C19 genotyping, 50% of patients received the genotyping, or all patients received 
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the genotyping. Demonstrating the feasibility of targeted genotyping, the results showed annual 
cost-savings to the plan in both the 50% and 100% testing scenarios, $222,426 and $444,852, 
respectively.  
 There exist several disadvantages to the reactive approach as well. Once the 
determination has been made to test, it must be "ordered, retrieved, and interpreted by the 
physician" before applying any changes to the patient's treatment.
22
 A slow turnaround time can 
lead to insufficient time being available before a clinical decision for drug therapy needs to be 
made. Additionally, clinicians may lack the knowledge on gene/drug relations to enable them to 
even initially order the appropriate tests when needed.
1
 Testing on a per-gene basis can lead to an 
increased cost if repeated tests are needed for complicated patients on multiple genetically 
dependent therapies.
 
 The author of the budget impact analysis described previously only 
considered the one genotype, he addresses the potential for further cost-savings from a 
preemptive genotyping approach that enables decreased testing costs for individual genotypes 
and integration with clinical decision support tools.
23 
  
 
Preemptive-Germline mutation testing 
 The alternative pharmacogenetic testing approach is to preemptively test patients for 
multiple pharmacogenetic variants. A large retrospective study on 52,942 medical home patients 
conducted by Vanderbilt University Medical Center (VUMC) found that almost 65% of patients 
were exposed to at least one medication with a drug label indicating a known pharmacogenetic 
variation in response during the five year time period, and 54% were exposed within a one year 
time frame. Using probabilities of medication exposure and probability of six possible severe 
12 
 
adverse events, the researchers estimated that 383 adverse events could have been prevented with 
the implementation of an effective preemptive genotyping program.
22 
 The ability to assay hundreds to thousands of genetic variants at a time can decrease the 
cost of individual genotyping, and provide genetic information that can be reused over the 
lifetime of a patient as other drugs are prescribed. Multi-gene testing in a single assay benefits 
the patient in another manner due to the fact that the pharmacokinetics and pharmacological 
effects of a great majority of medications are determined by multiple gene products. The 
adjustment of dosing based on a single-gene genetic test results, in some cases, can reveal 
genetic variants in other genes that might be of clinical importance.
 
Additionally, a single gene 
can affect more than one medication (TPMT, CYP2D6, CYP2C19, CYP2C9, HLA-B, DPYD, 
UGT1A1) and the preemptive availability of these results makes better use of this genetic data.
2 
New drug-gene interactions are discovered continually, and the use of multiplexed preemptive 
testing and successful clinical support tools will enable clinicians to apply immediately this new 
knowledge to improve patient outcomes. 
The St. Jude Children's Research Hospital protocol, PG4KDS, was opened in 2011 and as 
of the end of 2013, the results of four genes have been implemented into the EHR. This 
corresponds to 12 high-risk drugs and 55 clinical decision support systems. The data from this 
protocol also showed that 78% of patients had at least one actionable genotype result.
24 
Currently 
there are seven genes coupled with 17 high-risk drugs that have been integrated into the EHR.
25
 
Another study conducted in the VUMC Predict program preemptively genotyped 10,000 patients 
and found results, based on five drug-genome interactions, which identified one or more 
actionable variants in 91% of overall patients and 96% of black patients.
26
 The genetic data of 
9,589 individuals was compared with historical published allele frequencies. The authors point 
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out that it would have taken 14,656 total tests using a reactive genotyping approach, a nearly 
50% increase in the amount of testing. Current thought is that most actionable drug prescribing is 
linked to 12 genes. Dunnenberger et al. theorized that based on this, 98.5% of whites and 99.1% 
of blacks, would present with at least one high-risk diplotype.
1 
The utility of pharmacogenetic 
testing is contingent upon the prevalence of patients who receive high-risk pharmacogenetically 
driven drugs and have phenotypes that predict a variable response. Thirty of the most common 
prescription drugs considered pharmacogenetically high risk accounted for approximately 738 
million prescriptions in 2013.    
 
Implementing Preemptive Pharmacogenetic Testing in Practice  
 The Pharmacogenomic Research Network (PGRN) is at the forefront of preemptive 
pharmacogenetics and its successful implementation into the health care system. PGRN is a 
group of prominent researchers and clinicians at several academic hospitals throughout the U.S. 
that are coordinating with the National Institute of General Medical Science (NIGMS) and the 
National Institutes of Health (NIH) to study how genetic variation contributes to interindividual 
differences in responses to medication.
27
 Other than VUMC, there are several more highly 
regarded academic research medical institutions that are undertaking similar preemptive testing 
strategies. A few of these include St. Jude Children's Research Hospital, Mayo Clinic, Mount 
Sinai Medical Center, University of Florida and Shands Hospital, the University of Chicago, and 
Brigham and Women's Hospital.
1
  
The VUMC PREDICT program was created in 2010 to target "high value genetic 
variants" that contribute to medication-related adverse events through a preemptive genotyping 
14 
 
of patients. The relationship between variants of CYP2C19 genotypes and antiplatelet therapy 
was the initial focus. PREDICT uses the VeraCode ADME Core Panel to genotype their patients, 
testing for 184 variants in 34 genes associated with drug response.
1,28
 Four of the other 
institutions listed previously have implemented similar multi-gene preemptive pharmacogenetic 
testing platforms including Mount Sinai Medical Center (Sequenom iPLEX ADME 
pharmacogenetic - 36 genes), Mayo Clinic (PGRNseq - 84 genes), St. Jude Children's Research 
Hospital (Affymetrix DMET Plus Array - 230 genes), and University of Florida and Shands 
Hospital (Life Technologies Quant Studio Open Array - 120 genes).
1
  
 The actionability of a drug/gene relationship is ultimately dependent upon the translation 
of genome discoveries into systems that optimize the delivery of medications. An essential 
aspect of this actionability is the availability of alternative therapies when a high-risk genotype 
has been identified in a patient. This requires efforts by researchers to not only recognize the 
drug/gene relationship that may be harmful, but to also identify an alternative therapy.
2
 Work by 
the Clinical Pharmacogenetics Implementation Consortium (CPIC), has taken a leadership role in 
addressing this complex issue in pharmacogenetics. Many of these programs rely on the CPIC 
guidelines to provide the clinical evidence of the drug/gene pair that is being tested and 
potentially moved into the electronic health record (EHR). The importance of the EHR and 
clinical informatics in the dissemination of preemptive pharmacogenetics has not been 
overlooked. Many of the institutions mentioned above have developed clinical decision support 
tools personalized to the high-risk medications likely to be prescribed based on the preemptive 
testing results. St. Jude Children’s Research Hospital published a detailed report on the 
development and use of their system.
29
 Entries are created for high-risk phenotypes that deliver 
post-test alerts when the high-risk drug is prescribed. The CDS system will also alert the 
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clinician when a high-risk medication is prescribed prior to genetic results being entered into the 
patient’s EHR. The mission of CPIC is to inform clinicians on how genetic test results should be 
used to improve patients’ outcomes, not when and whether to use them.30  
The University of Chicago’s "1,200 Patients Project" aimed to determine the relevance of 
pharmacogenetic results while delivering care in an outpatient clinic. As of 2014, 812 patients 
had participated and 608 have been successfully genotyped. This protocol used the result signals 
green light (favorable), yellow light (caution), and red light (high risk) via a genomic prescribing 
system (GPS). At 268 clinic encounters, 86% of physicians accessed the GPS with 57% green 
lights, 41% yellow lights, and 1.4% red lights. Also, physician click frequencies were reported as 
20%, 72%, and 100%, respectively. This information shows a high rate of physician adoption 
and widespread use in the patient population.
31 
Approximately 15% of European Union-European Medicines Agency (EU-EMA) and the 
US-FDA approved medications have some type of pharmacogenetic data in the label.
32,33
 
According to CPIC, only about 7% of these medications have actionable germline 
pharmacogenetics.
 
However, a disproportionate amount of these medications (  18%) represent all 
prescriptions in the United States.
2
 Though only representing a small portion of the total 
medications consumed in the U.S., the potential for improving current patient outcomes exist and 
will be expanding as more actionable drug/gene relationships are identified. The design of CPIC 
was realized through a collaboration of PGRN and NIGMS, described above, on the view that 
preemptive genetic testing will become more widespread and clinicians will need the appropriate 
evidence to make informed and accurate decisions quickly.  
16 
 
 The guidance that CPIC provides to clinicians is based on standardized guidelines to 
understand the types and levels of evidence needed to justify the implementation of 
pharmacogenetics into clinical practice. This evidence includes:  
"…sound scientific rationale linking genomic variability with drug effects, the 
therapeutic index of the involved medications, the severity of the underlying disease, the 
availability of alternative dosages or drugs for patients with high-risk genotypes, the 
availability of CLIA approved laboratory tests, and peer-reviewed clinical practice 
guidelines that incorporate pharmacogenetics in their recommendations."
34
 
Each guideline contains a summary of the drug dosing addressed from the genotype tests, a 
literature review, genetic test interpretation for clinicians, population studies to compliment this 
interpretation if available, genetic test options, possible incidental findings from the test, linkage 
of genetic variability to variability in drug-related phenotypes, and levels of evidence and 
strength of recommendations.  
 The prioritization of CPIC gene/drug pairs uses a subset of two rating schemes adapted 
from National Academy of Clinical Biochemistry for the quality of the evidence and the National 
Institutes of Health for the strength of the recommendation.
34
 CPIC will apply this approach to 
the development of each guideline. 
The schema for evaluating the quality of evidence for a linkage between drug-related 
phenotypes to specific genetic variations is as follows:
  
Level 1: the evidence includes consistent results from well-designed, well-conducted 
studies 
17 
 
Level 2: the evidence is sufficient to determine the effects, but the strength of the 
evidence is limited by the number, quality, or consistency of the individual studies, by the 
inability to generalize to routine practice, or by the indirect nature of the evidence. 
Level 3: the evidence is insufficient to assess the effects on health outcomes because of 
the limited number of studies, insufficient power of the studies, important flaws in their 
design or in the way they were conducted, gaps in the chain of evidence, or lack of 
information. 
The schema for evaluating the strength of the recommendation to clinicians involved in decision 
making is as follows:
  
A: strong recommendation for the statement 
B: moderate recommendation for the statement 
C: optional recommendation for the statement 
 
 CPIC is a joint project with PGRN and the Pharmacogenomics Knowledge Base 
(PharmGKB), which is managed by Stanford University and trademarked by the U.S. 
Department of Health and Human Services (HHS) that "encompasses clinical information 
including dosing guidelines and drug labels, potentially clinically actionable gene-drug 
associations and genotype-phenotype relationships."
35
 PharmGKB uses a similar rating system to 
the one listed above but focuses rather on the genotype-based pharmacogenomic summaries of 
the association between a drug and particular variant. These clinical annotations are assigned a 
level (1A, 1B, 2A, 2B, 3, and 4), in descending order of strength of evidence for the association, 
based on population, replication, effect size, and statistical significance.  
18 
 
 There are currently 36 variant-drug combinations that are listed level 1A. PharmGKB 
defines level 1A as the "annotation for a variant-drug combination in a CPIC or medical society-
endorsed pharmacogenetic guideline, or implemented at a PGRN site or in another major health 
system."
36
 CPIC has designated its levels for gene-drug pairs as either: A, B, C, D. It is important 
to note that these are not the same as the clinical annotations of PharmGKB, although there is 
some overlap. There are currently 41 gene-drug pairs that have the designation CPIC Level A 
and 97 designated CPIC Level B. Level A means that at least one moderate or strong action 
(change in prescribing) is recommended, while level B indicates at least one optional action is 
recommended. The PharmGKB annotation levels are incorporated in the prioritization process of 
CPIC guidelines of new gene-drug pairs. There are currently 30 guidelines available. A flow 
chart of this process is illustrated in Figure 1.
37
 For a full list of the clinical annotation levels of 
evidence from PharmGKB and a visual of the PharmGKB Knowledge Pyramid see Appendix A. 
 
Figure 1. CPIC evidence level selection process flow chart 
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 Although several academic institutions have implemented preemptive testing and efforts 
are made to provide guidance on how to use the test results, the challenge of implementing a 
change in routine medical practice is a real issue. The complexity, size, and momentum to resist 
change can stymie an innovation such as pharmacogenetics from clinical implementation. This 
can even occur when the change is likely to lead to improved care. For the numerous positives 
that have been researched and put forth by proponents of pharmacogenetic testing, there still 
exist barriers to effective implementation. Work by the VUMC PREDICT program identified the 
following challenges: "the assessment of the potential benefits for clinical pharmacogenomic 
testing, definition of the target populations, designation of anticipated scope of 
pharmacogenomic testing, determination of diagnostic methodologies, development of 
infrastructure to support reporting, interpretation and use of results, and establishment of 
reimbursement for testing."
26 
  The focus of this research is to gain further understanding of the last challenge identified 
in the previous list, "the establishment of reimbursement for testing." Third- party payers provide 
a highly valued perspective on the challenges outlined in the VUMC PREDICT program. The 
establishment of reimbursement policies for preemptive pharmacogenetics will be facilitated by 
addressing the other challenges and a detailed look into the decision making process of the payer 
should reveal some methods to move forward. 
 
The Role of the Payer 
 The role of the payer cannot be understated in the adoption of pharmacogenetic testing as 
standard of care. Third-party payers will need adequate evidence to justify coverage decisions 
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and provide the incentive for clinical practice to adopt this technology so that the potential 
benefit to patients can be realized. Three types of policies are developed within a third-party 
payer organization: the medical policy, coverage policy, and payment policy. The first is based 
on scientific evidence and does not consider financial issues. The second is the most familiar to 
the average person since it represents the contract between the purchaser and the issuer of the 
policy and the scope of the benefits therein. The last is the policy between the issuer and the 
practitioner that receives reimbursement for utilization of the service, in this case, the 
pharmacogenetic test.  
It is important to remember that coverage policies and reimbursement represent two 
different things.
38
 Developing these policies requires studies from professional and academic 
researchers to guide decision-making. The evidence required to build a medical policy is the first 
barrier that must be overcome for pharmacogenetic testing to move forward. The specific types 
of studies that payers desire has been ascertained by the research of Leung et al. and ranked 
according to their importance as evidence: randomized clinical trials (RCTs), systematic reviews 
(including comparative effectiveness research (CER)), review articles, professional society 
guidelines, prospective observational studies, budget impact, cost and economic, and 
retrospective observational studies.
39
 All of these score somewhere between a 3 and 4 on a 5 
point Likert-type scale with the exception of the RCT, which received a score of 4.4. It needs to 
be noted that the researchers found that the payers did not express concern for using 
observational data from their own organization in coverage decisions.
 
 Previous literature on how payers are approaching pharmacogenetic testing at their 
organizations has revealed some fairly consistent themes with regards to the evidence payers 
require when assessing a new health technology. A health technology assessment (HTA) is 
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research that is pursued, in this case, by a third-party payer organization, to assess the short- and 
long-term consequences of the technology. The properties that are evaluated for new health 
technologies are numerous: safety, efficacy, cost-effectiveness, ethics, legality, and politics. An 
ISPOR publication identified five activities that define a formal HTA: horizon scanning, topic 
determination, collection and assessment of evidence, appraisal, and funding and policy 
implementation.
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 The adoption of pharmacogenetic testing has been hindered by the third 
activity, the collection and assessment of evidence, which ultimately hinders the last two 
activities in the list.  
The hindrance in this activity is not that evidence does not exist, but rather the type of 
evidence that payers find useful in their evaluations does not currently exist. The diversity of 
available genetic tests corresponds to the variability in how a payer will approach a coverage 
decision and the strength of the evidence seems to be guiding the process. A study in 2010 
examined six case studies of personalized medicine tests of varying types: disease 
differentiation, pharmacogenetics, and genetic predisposition. They compared coverage 
decisions among five large private and public payers and found that the pharmacogenetic tests, 
with current evidence of observational genotype-phenotype studies, were not at all or not usually 
reimbursed.
6
  
 Current coverage of disease diagnosis, risk, prognosis, as well as pharmacogenetic tests is 
low. A study published in 2012 by Hresko and Haga using an online search of the top dozen U.S. 
health insurers found that 18% of tests for disease diagnosis/risk/prognosis, and 30% of 
pharmacogenetic tests, were covered. Thirteen of the twenty-seven pharmacogenetic tests that 
were reviewed included an FDA drug label with pharmacogenetic information. The majority of 
the pharmacogenetic tests were deemed investigational and not medically necessary.
3
 The 
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reluctance to reimburse seems to stem from three major concerns: a lack of clinical utility, tests 
that are medically unnecessary (defined as lacking the FDA requirement of the test), and lack of 
cost-effectiveness analysis and/or comprehensive comparative effectiveness analysis.
41
  
The expectation of clinical utility and comparative effectiveness is evidenced by the fact 
that payers decline to pay for a pharmacogenetic test costing, many of which are less than $500, 
while agreeing to cover drugs (for which the test could be used) that are much more expensive.
5
 
The difficulty assessing clinical utility in pharmacogenetics is exacerbated by the complexity and 
burden of the randomized control trial, the evidence-based driven gold standard of clinical 
utility. The requirement of a large cohort of heterogeneous patient populations, placebo effects, 
and drug response variabilities frequently result in a small incremental clinical benefit. Lam 
attributes this to the fact that pharmacogenetics emphasizes the safety and efficacy of outlier 
patients, poor and ultrarapid metabolizers, as well as non-responders and those susceptible to 
ADRs. Suggestions of clinical trials with smaller, targeted patient populations likely to respond 
or not suffer ADRs have been one of the proposals to address the challenges of traditional RCT 
assessment for safety and efficacy using pharmacogenomic biomarkers. Scientific and clinical 
communities continue to debate the balance between the current required level of evidence of 
clinical utility and those realistically achievable but still scientifically appropriate.
41
  
 An in-depth investigation into the decision making process of six payers provided a look 
past the basic need for clinical evidence. It examined policies around one genetic test, considered 
a blend of diagnostic/risk and pharmacogenetics that has received coverage by all insurers, the 
Oncotype Dx test to assess breast cancer recurrence risk and subsequently guide treatment 
decisions.
42
 Four of the six payers indicated that they were willing to base their decisions on the 
intermediate endpoint of clinical utility, defined as evidence the test affected clinical decision 
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making. While the payers stated that they valued clinical effectiveness most highly, their 
perceptions of its strength varied greatly. To help the payers overcome a lack of clinical evidence 
in some instances, patient and provider adoption, of the penis fragment coverage by a California 
Medicare Administrative Contractor (MAC), and endorsement of a medical society, along with 
intermediate clinical utility, were considered as important health system factors in developing 
policy decisions. 
 Although the Oncotype Dx did have prospective clinical trials, this exposé on the 
decision-making processes of those who have adopted Oncotype Dx can provide other factors of 
investigation when a new medical innovation may face uncertainty in clinical evidence. Further 
study of variations among coverage policies for the technologies associated with precision 
medicine might facilitate a more homogeneous adoption by educating the decision makers and 
promoting less discontinuity among physicians and patients.  
 Slower payer adoption has affected the adoption of pharmacogenetic testing by health 
care organizations, providers, and patients. Slow payer adoption can be attributed to three main 
factors:  lack of clinical trials to show the clinical validity of the test, little evidence that 
pharmacogenetic testing has influenced clinical practice decision making and improves patient 
outcomes, and whether pharmacogenetic testing is cost-effective to their plan. There have been a 
few studies that have attempted to understand the third-party payer's point of view on this topic 
through in-depth interviews. To our knowledge, no studies exist to capture the opinions of the 
third-party payer with respect to preemptive pharmacogenetic testing.
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3. METHODOLOGY 
Study Objectives 
The study purpose is to investigate the perspectives and opinions about coverage and 
reimbursement policies for preemptive pharmacogenetic testing of third-party payers. The 
following objectives are to provide the necessary details to achieve the study purpose: 
1. Describe the current policies third-party payers have on pharmacogenetic testing and how 
these policies differ by the type of test 
2. Describe the clinical evidence of effectiveness that third-party payers require for policy 
decisions on preemptive pharmacogenetic testing  
3. Describe the third-party payers’ perceptions of value with respect to pharmacogenetic 
testing and the cost factors associated with preemptive pharmacogenetic testing coverage 
decisions  
4. Identify the practice/utility factors that third-party providers are using to make coverage 
decisions for preemptive pharmacogenetic testing 
5. Identify barriers and facilitators to third-party payer coverage of preemptive 
pharmacogenetic testing. 
Sample 
 Utilizing a payer panel made available by Medical Marketing Economics, LLC, third-
party payers were invited to participate. No initial honorarium was offered to participants. A 
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targeted final sample size of 15 payers was desired for the in-depth interviews, which is 
consistent with previous work conducted in this area.
4,5 
Interviews were conducted until 
saturation of topic responses was achieved.  
 
Data collection 
 Qualitative in-depth interviews were conducted via telephone, bookended by two 
quantitative surveys administered online (Qualtrics, Provo, UT). A first invitation email (see 
Appendix B) was sent to all members of the panel along with a brief online screening survey. 
The screening survey asked about the participant’s professional capacity in their institution, size 
of their plan, and the number of lives covered, as well as the breakdown of plan types for their 
beneficiaries. The screening survey also assessed levels of familiarity, management, and priority 
of health technologies and pharmacogenetics at the institution using several Likert-type item 
questions. The screening survey concluded to assess respondents’ familiarity with preemptive 
pharmacogenetic testing. The survey can be found in Appendix C. 
  Those respondents who answered "not at all familiar" on the question "Please rate your 
level of familiarity with all types of pharmacogenetic testing” were not be eligible for the 
interview. All eligible payers received a second invitation email (Appendix D), to participate in 
the in-depth interview portion of the research. In the second email pre-read material was 
provided to the participant and included descriptions of different types of genetic testing, 
diagnostic, pre-symptomatic, and both reactive single-gene and preemptive multi-gene 
pharmacogenetic testing. The work of the CPIC and PharmGKB on the clinical validity of the 
drug-gene relationships that drive the actionability of pharmacogenetic testing was also 
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presented to the participant. An example from the PharmGKB website 
(https://www.pharmgkb.org/guideline/PA166128738) of the clinical decision alerts a clinician 
might encounter based on the CPIC work was also provided. Non-responsive potential interview 
respondents were sent a reminder email containing the same information one week after the 
initial email.  
 The brief quantitative survey and discussion guide for the in-depth interview were 
reviewed for face validity with a group of pharmacogenetic experts that have active involvement 
in the use of these technologies, or are heavily involved in the academic research of 
pharmacogenetics. After review, the guide and survey were updated to assure concise and 
informative questions were presented. The first interview acted as a pre-test for the interview 
guide used in the remaining interviews. Subsequent updates to the guide were made when 
several questions were found to be unnecessary, and thus removed, while others were rephrased 
to more accurately convey the intended questions. The interviews were digitally recorded for 
analysis. Verbatim transcription was completed by a professional transcription service as the 
interviews were completed. The semi-structured interview guide will be described in greater 
detail below.   
At the conclusion of the interview the participant was instructed to follow a web link to 
complete a brief survey. This survey contained nine Likert-type questions that were originally 
included in the semi-structured interview guide, but after the pre-test interview these questions 
were deemed to function better as a stand-alone survey to summarize the conversation. 
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Semi-structured Interview Guide 
The interview guide has two sections: an introductory section and a section containing 
three themes found in the pharmacogenetics literature. The first section contains seven questions 
to assess the participant's attitudes toward pharmacogenetic testing more generally, including any 
high level perceptions of the precision medicine and current policies they might have on different 
types of pharmacogenetic testing. This number was reduced from 12 questions to 7 questions 
after conducting the pre-test discussion/interview. The second section examines barriers to 
further implementation of pharmacogenetics and key drivers of payers’ coverage policies with 
regards to pharmacogenetics.
2,4,5,10,39,40,41,43 
It originally included 17 questions split among these 
themes, but was also reduced to 14 and tailored based on face validity and pre-test discussions. 
The specific pharmacogenetic themes covered in the second section of the interview 
guide include: clinical utility and validity of pharmacogenetic tests, perception of value and cost 
factors associated with pharmacogenetic tests, and coverage and reimbursement issues for 
pharmacogenetic testing. The semi-structured interview guide can be found in Appendix E. 
 
Data analysis 
 The results of the screening questionnaire were analyzed and responses to the surveys 
were aggregated to obtain frequencies. This same information was parsed out for those payers 
that were eventually interviewed (n=13, one did not complete the post-interview survey) and the 
data are available in Table 1 and Table 2. A visual comparison was conducted to determine if 
there were any striking differences among those survey respondents that agreed to the interview 
and those that did not. An independent samples t-test was run to determine if there was any 
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significant difference, between the respondents that were interviewed and those that were not, on 
the items in the screener survey.  
 The qualitative interview portion of the study was analyzed as a content analysis. This 
content analysis is a blend of inductive and directed (sometimes referred to as deductive) 
strategies. As outlined in the description of the interview guide there were a number of pre-
identified themes introduced in the interview based on previous literature. However, respondents 
were allowed to direct the conversation as they saw fit.  More specifically, questions in each 
theme were allowed to shift to another theme and new themes or subthemes were created if the 
data strongly indicated such. The inductive research approach has been identified as the most 
appropriate for relatively undeveloped areas of knowledge.
44 
The blend of pharmacogenetics and 
third-party payer opinions, underdeveloped and developed, respectively drove the decision to 
pursue a blended qualitative research design. A decision was made to code and analyze the 
transcripts manually instead of utilizing qualitative data analysis software. Although software 
may save time and assist in the validity through increased rigor, this process can become 
deterministic and focused inappropriately on the volume of data instead of the quality, distancing 
the researcher from their data and potentially losing context and meaning.
45
 With a topic focused 
on an underdeveloped area of knowledge, this approach seemed inappropriate.  
 The transcripts were fully analyzed by the study lead and one other author to identify the 
driving themes of the data. Each transcript was read three times by these two researchers. During 
the first read through readers highlighted important statements made by the respondent and 
provided a brief summary of the highlighted portion to identify the topic therein described by the 
highlighted material. This is also known as meaning units. In a second read, the readers 
identified codes from the first read through that appeared in a majority of the interviews and 
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determined main themes and subthemes. A third read through was conducted to ensure no 
important data were left undiscovered by comparing each interview to the themes and subthemes 
identified. A third researcher was asked to mediate any disputes between the two other readers to 
arrive at a consensus.
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4. RESULTS 
 The initial sample included 35 respondents to the screener survey. Six responses were 
ineligible for any type of analysis due to incomplete responses leading to a final sample size of 
29 respondents for the survey. As expected, payers were less familiar with preemptive 
pharmacogenetic testing. Over three-quarters of respondents were somewhat, slightly, or not at 
all familiar with preemptive pharmacogenetics.  
 Of these 29 complete respondents, 14 agreed to participate in the interview by responding 
to follow-up emails. This consisted of nine pharmacy directors and five medical directors. Three 
of the five medical directors proved more difficult to recruit and in an attempt to balance the 
sample, a modest honorarium was offered to three medical directors.  
 Table 1 provides an overview of the demographics of the interview participants and 
Table 2 provides data on the remainder of the questions from the screener survey. These 14 
payers accounted for nearly 122,000,000 million covered lives or almost 40% of the U.S. 
population. Plan size ranged greatly from 200,000 to as many as 50,000,000. These individuals 
interviewed came from various types of organizations including: large traditional payers at the 
national and regional level, national and regional pharmacy benefit management companies 
(PBMs), group model health systems, individual medical groups that offer insurance, and 
others. No two individuals interviewed were from the same health plan. However, some amount 
of “double-counting” is possible between the PBM and traditional payers. Based on the visual 
comparison of the data there did not seem to be any differences between those that agreed to the 
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interview and those that did not. The independent samples t-test comparing the respondents in 
the two groups did not reveal any significant differences. However, this t-test should be 
interpreted accordingly due to the small sample size.  
Demographics of interviewed payers (N=14) Mean 
Standard 
Deviation 
Minimum Maximum 
Number of lives covered on plan 8,708,898  15,815,280  200,000  50,000,000  
Commercial PPO/POS (%) 47.5  35.8  0  100  
Commercial HMO (%) 24.3  24.7  0  75  
Medicare (%) 11.4  9.9  0  25  
Medicaid (any) (%) 16.4  23.1  0  85  
Other (%) 0.4  1.3  0  5  
Length of time beneficiary stays with organization (years) 4.9  2.7 2 10 
      Table 1. Screener survey demographics 
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Results of remaining screener survey questions for interviewed payers % of respondents 
Organization has official health technology 
committee (N=13) 
Yes 50.0 
No 42.9 
Not sure 7.1 
Organization as an adopter of new health 
technologies (n=13) 
Early adopter 7.1 
Early majority adopter 28.6 
 
Level of familiarity with all types of 
pharmacogenetic testing  
Late majority adopter 64.3 
Very familiar 7.1 
Moderately familiar 35.7 
 
Level of management of pharmacogenetic testing 
relative to other health plans (n=13) 
Somewhat familiar 42.9 
Slightly familiar 14.3 
Highly managed 7.1 
Moderately managed 28.6 
 
Level of familiarity with preemptive 
pharmacogenetic testing 
Somewhat managed 28.6 
Slightly managed 28.6 
Very familiar 7.1 
Moderately familiar 14.3 
 
Preemptive pharmacogenetic testing discussed at 
P&T/medical technology meetings 
Somewhat familiar 28.6 
Slightly familiar 28.6 
Not at all familiar 14.3 
Yes 23.1 
No 64.3 
 
Formal approach to covering preemptive 
pharmacogenetic testing  
Do not know 7.1 
Yes 15.4 
No, but in the process of putting 
one together and will have one in 
the next few years 
46.2 
 
Aware of clinical setting implementation of 
preemptive pharmacogenetic programs 
No, and no current plans for the 
future 
38.5 
Yes 15.4 
No 84.6 
Table 2. Screener survey non-demographic data 
 
Content Analysis 
 The majority of interviews lasted between 30 and 45 minutes, however one lasted 75 
minutes. All respondents were given the opportunity to review the material before beginning the 
interview. The data from the interviews revealed three themes: clinical utility, economic utility, 
and policy development. These correspond closely with the pre-categorization of the discussion 
guide. Each of these themes had several sub-themes that will be discussed in detail below.   
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Clinical Utility – A world of potential with lacking clinical evidence 
 Payers believe there is potential value in having the pharmacogenetic data available for 
clinician decision making, but remain skeptical that this data is currently providing evidence that 
leads to better clinical outcomes for patients. This guiding idea on current clinical utility was a 
major barrier for widespread adoption and coverage in the payer mind. This concern seemed to 
come from a lack of objective outcomes level data:  
"Now what needs to be tied to…is products A and C work better with this patient, 
than product B and D for patient two based on the genetic profile as far as 
outcomes improvement; survival, lower exacerbation, delay in correction, higher 
level of control, duration medicine." Pharmacy Director #1 - Large National 
Health Plan. 
"If there's evidence...[the patient] should get preemptive testing, I'm willing to 
consider that... Drug reactions are the number one problem and drugs that don't 
work, drugs that cause more harm than good. I'm open to any of it, I just need to 
see the evidence." Medical Director #1 - Large Regional Health Plan 
Many saw pharmacogenetic testing as something that would become standard practice when 
prescribing medications in the future, but expressed doubts it was going to become pervasive in 
the next five years.  
There were four sub-themes identified under the main theme of clinical utility: potential 
value of pharmacogenomics, CPIC and actionability, types of clinical data needed, and testing 
versus monitoring. The “potential value of pharmacogenomics” was asked explicitly to some 
participants while others offered up their opinion without prompt. Adding to what was 
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aforementioned; payers see potential value to both patients and the health system but remain 
apprehensive.  
"Tremendous potential, tremendous potential to help us much better refine who 
we give drugs that often have to be targeted for large populations with a fair 
amount of variability and drug response. But that being said, at the present time 
they are relatively low on the value scale." Medical Director #2 - Drug Benefit 
Collaborative with medical policy management 
Value was also subject to the type of pharmacogenetic testing payers were using as a basis for 
their answer. While germline pharmacogenetics, and the pharmacokinetic and pharmacodynamic 
properties affected by genetics, was the focus of the interviews, payers frequently referred to the 
companion diagnostics associated with cancer drugs because they were more familiar with them. 
In fact, several payers made it clear that they desired a test that would provide them with yes or 
no decision on the reimbursement of a test, “We're looking for a test where we can make the 
physician accountable, either a yes or a no.  Not something that there is a 70% likely response 
versus a 40% likely a response” Medical Director #4 - Large National Health Plan. This led to 
the observation that many payers were unaware of pharmacogenetic testing outside of scope of 
companion cancer diagnostics, and as such their expectations were somewhat out of step with the 
information these tests could provide.  
 The second subtheme, “CPIC and actionability”, focused on payers reactions to the work 
of this organization and how the data it generates could be used in pharmacogenetics. 
Interestingly, almost all payers were unfamiliar with CPIC and PharmGKB and the 
corresponding rating scales and guidelines being developed and payers were pleasantly surprised 
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by the work being conducted. However, the previous discussion about the ability to make a yes 
or no decision based on these tests was reiterated in responses to the perceptions of CPIC. 
Multiple payers used the term "gray area" to describe the lack of clarity on making a yes or no 
decision with these tests.  
"The challenge is if it’s A, then can I say, yeah, it should be built in policies; if 
it’s D, then I’m gonna say I’m not gonna cover this. But if it’s B or C, I can’t 
make a – I can’t enforce a decision or a policy around that. So, no, this is – it 
might help physicians guide, but, again, it’s a guidance and it’s not something that 
a payer can definitively use to make a decision on. That’s the challenge." 
Pharmacy Director # 5 - PBM w/ medical policy   
Given the lack of current use in coverage decision-making, CPIC guidelines were viewed mostly 
favorable in the context of their incorporation into the electronic health record (EHR). 
Interviewees felt that CPIC could provide incremental benefit by guiding prescribing.  
"If you have a particular drug where a test said this (medication dosage) needs to 
be reduced, this is not just based on – I would speculate to say that this is 
compelling data. Those things can be built in as alerts. The electronic record, 
dysfunctional as it is, can be useful for that." Medical Director # 3 - Medical 
group offering insurance 
An unprompted discussion also occurred with several payers on the similarities of CPIC 
with others such as the National Comprehensive Cancer Network (NCCN) guidelines for cancer 
treatments. Payers communicated that expanding the breadth of their (CPIC) work could increase 
their credibility, but stopped short of saying they would reimburse based on these guidelines.  
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"They (NCCN) started creating interest as far as should you cover this, should 
you not cover that, we rate this one a 2A, we rate this one a B. They have 
different ratings for the drugs. That really hadn't happened in a long period of 
time at all. I think that, that model could be used in something like this." Medical 
Director # 3 - Medical group offering insurance 
 The next sub-theme “clinical data” specifically focused on the kinds of clinical data that 
would be useful to payers and stemmed from previous literature suggesting that the RCT may be 
an unnecessary financial burden, particularly for previously approved and post-marketed drugs. 
These discussions provided a wide array of responses:  
"I quite frankly do think you need the randomized control trials.  Those clinical 
reports may be helpful.  If you're going to do this, it really depends on the disease 
process in terms of that.  You have to establish an outcome." Medical Director #4 
- Large National Health Plan.  
"You almost wonder if the best way to do this is in some kind of real-world type 
of population based study where you test a large group of people and then look 
retrospectively to see if you can then document a rationale for maybe a drug 
problem or a failure to respond they had in the past." Medical Director #2 - Drug 
Benefit Collaborative with medical policy management 
The number needed to “test” or NNT calculation was a topic frequently brought up by 
payers without any explicit mention of the topic. A NNT is traditionally known as “number 
needed to treat” but in this case, interviewees shifted it to be number needed to “test”. More 
specifically payers defined this as the number of pharmacogenetic tests needed to be 
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administered to avoid one additional adverse outcome. Payers made it clear that this was 
something that physicians, and themselves, will use frequently when evaluating the utility of a 
new treatment or technology.  
"You know, again, like anything else, if five percent of the patients are avoided, I 
don't know if it's worth it. If 40 percent have a drug change or are avoided, 
depending on the cost of the test, it may be worth it. So, it's going to be the 
number needed to test, sensitivity, specificity, actionability." Medical Director #5 
- Large Regional Plan 
Some payers also questioned the notion that doing an RCT on only patients who are known to 
respond would only help those patients, citing a potential benefit for other patients where the 
drug works but maybe just not as well.  
 The last subtheme, “testing vs. monitoring”, under the main theme of clinical utility  was 
more inductive in nature as it developed naturally from many of the discussions with 
interviewees. The debate was one that compared the standard of care for clinical prescribing; 
dosing and administering one product and waiting to see how the patient responds and if changes 
need to be made the physician adjusts and waits again, to the use of a preemptive 
pharmacogenetic test (or reactive) to guide potentially more accurate initial dosing…"If it’s a 
very low cost drug you know, you try one and then maybe try another.  Because one of the 
concerns was some of the testing is that it’s going to lead you to maybe pick first line." 
Pharmacy Director #6 - Large National Health Plan 
This quote shows how payers viewed this testing through the lens of cost by type of drug. 
Again, the tests payers were most familiar with were the companion diagnostics for high priced 
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cancer drugs where no generic or low cost alternative exists. One payer challenged the 
applicability of preemptive pharmacogenetic testing and its benefit to patients by being available 
in the EHR at the time of initial prescribing... 
"The question is, is that test going to delay intervention? We are waiting for the 
results. How long does waiting two or three days or a week for test results really 
going to impact outcome? So I don't know. I don’t know that I am too concerned 
about the length of the test - or how long it would take to get the results of a 
particular test." Pharmacy Director #7 - Large Regional Health Plan 
Economic utility – The cost burden of organization wide testing and issues in calculating 
downstream economic benefits 
The importance of pharmacoeconomic research in this space is important, most likely as 
a result of the large upfront costs of widespread testing. Economic utility in healthcare typically 
refer to cost utility analyses and are considered in concert with a demonstration of clinical utility. 
There are no subthemes under this major theme as the discussion focused on the topic of the 
costs of widespread testing and what potential cost offsets could be realized from testing. The 
payers’ familiarity with cancer diagnostic pharmacogenetic tests again seemed to guide their 
perspectives on this discussion. For example they cited a willingness to pay for a test that costs 
several thousand dollars when associated with an extremely high priced cancer drug.  
"Okay, I'll spend a few hundred dollars or even a couple thousand dollars on a 
genetic test if it tells me the best way to handle a $100,000 a year anti-cancer 
therapy. That's a no-brainer. Now, let's think about pharmacogenetic testing that 
you're going to apply to large populations. Theoretically, you don't have to do it 
37 
 
multiple times... Let's say it's even a ridiculously low, low price of 100 bucks. If I 
got a million members that I got to test, I just spent a (hundred) million dollars 
and I don't know what my return on that investment is going to be." Medical 
Director #2 - Drug Benefit Collaborative with medical policy management 
 As evidenced by this quotation, payers are either unaware or do not have the sufficient 
data that the potential economic utility behind the preemptive is the ability to avoid adverse drug 
events, and subsequent hospitalizations and additional medical procedures. As such the payers 
were probed on this subject. Still the payers can only conceptualize this idea because of a lack of 
exposure to that data.   
"...if you are going to identify a responder knowing full well that six weeks down 
the road they may switch to something else, but now you know they are not 
because you know they are going to respond then yeah I could see some cost 
savings associated with that...If you know that patients are going to not develop a 
certain adverse event and therefore going to be more compliant on their therapy 
because it is better tolerated or they don't have to be hospitalized,... again I see 
that more as a cost benefit; but downstream though." Pharmacy Director #7 - 
Large Regional Health Plan 
This perception of downstream costs being prevented was something that payers valued, but at 
the same time they find using these cost offsets difficult when making coverage decisions.  
"Would we focus it on where we had potential risks either in preventable 
admissions or hospital readmissions and have offsets? Yes. I think when it trickles 
down through all that triage, to what’s good for society and good for the patient to 
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get an earlier experience, I’m (going to) suggest probably funding and resources 
run out before we get to that level of compassion and empathy. Ideally, I think 
that’s great, but I don’t think that’s real world." Pharmacy Director #6 - Large 
National Health Plan 
Payers have demonstrated concern that testing large numbers of people will most likely strain 
their organization. Although they also speculate that they might realize some cost benefit in 
avoiding additional medical services from testing, the costs are secondary or downstream in 
their prioritization. They currently lack the information needed to predict how patients will use 
this technology, and thus the ability to make an accurate decision on who to cover.   
 Many payers also had concerns about potentially large upfront cost of the preemptive 
technology. To investigate this, payers were presented with a hypothetical price scenario in 
which a multi-gene preemptive pharmacogenetic test was double the cost of a single-gene 
reactive pharmacogenetic test, $500 versus $250. They were asked to consider whether that price 
difference was enough to deny reimbursement of the more expensive test if ordered by a 
physician to guide drug selection. All but one payer that was asked to speculate on this scenario 
concluded that the price difference was not large enough to deny reimbursement of the $500 test. 
"That's a good question. I think again the answer is yes because again, we're not 
selecting a small subset of the population saying, "Okay, on this subset I'm going 
to do the $500 test instead of the $250 test."  You're committing yourself to doing 
a fairly substantial expense on a large number of patients. The problem you're 
going to run into there is again a big upfront cost for unknown value down the 
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road." Medical Director #2 - Drug Benefit Collaborative with medical policy 
management 
This scenario was proposed to the payers as a hypothetical to investigate whether current 
approximate price differences between multi-gene and single-gene tests were substantial enough 
to affect decision making. The answer appears to be that it is not, and this might allow for some 
slow integration of multi-gene testing into the system. 
Policy development – Population health and the role of other influential stakeholders  
 Influence from other stakeholders coalesces to provide the payer with another level of 
considerations beyond just clinical and economic data when evaluating pharmacogenetic testing. 
The policy development theme evolved from a variety of topics that contributed to the payer 
decision-making. Numerous subthemes were identified; many of these were drawn from an 
explicit line of questioning including the effect of CMS and the FDA on third-party payer 
policies, the stratification of beneficiaries receiving pharmacogenetic testing, and the role of 
active preemptive pharmacogenetic implementation. 
The first subtheme “population health” developed more implicitly due to several 
particularly interesting conversations examining the potential utilization of preemptive 
pharmacogenetics as a standard preventive health screening. A recommendation from the U.S. 
Preventive Services Task Force was discussed as a potentially influencing widespread adoption 
and coverage of preemptive pharmacogenetics. 
"The other way it could be is all plans and payers have annual refreshment and 
linkage to preventative health guidelines in quality metrics when it’s used... If it 
ever became a part of an annualized preventative health guideline, published and 
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adopted and/or became a quality metric that will help you, then it would become, 
and we would pay for it." Pharmacy Director #9 - Large Regional Health Plan - 
High proportion of Medicaid beneficiaries 
The concerns being communicated with regard to the high cost of organization or population 
wide testing, as discussed previously, allowed a probe into potential considerations to attenuate 
this barrier. 
In light of the difficulties with population health widespread adoption, payers were asked 
to speculate on if they would consider the stratification of beneficiaries to those over a certain 
age or those with co-morbidities increasing their need for certain pharmaceutical products. This 
was met with variable response as some payers were willing to consider this as a possibility, 
while others found it difficult and potentially unethical to choose which beneficiaries might be 
offered such a technology.  
"I think that if you have a patient that's 60 years old and they're relatively healthy, 
you may have already done this but you may decide that at that age 60, it's time 
that he has or she has this information in his file so the $500 gets spent. I think 
that's going to be really up to the physician on how they view the patient. But I 
don't think we are going to go out and promote a multi-gene testing for everybody 
over 65 or everybody over 60 just because the consortium or the guidelines or 
whatever say that is the right patient for these." Pharmacy Director #2 - Regional 
Health Plan 
"I don't think that we would ever do anything like that.  I do not think that would 
be anything legal would ever allow... "Well, if you have these underlying 
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conditions then you can do a preemptive."  If you don't, "Eh, so sorry. Until we 
develop something, we're not going to test you."... If there was requirements or 
guidance along those lines, then plans of course would be obligated to comply.  
That's more or less government taking a stand now." Pharmacy Director #4 - 
Large National Health Plan 
The diversity in response to this question again demonstrates the level of uncertainty in this 
space. In concert with other levels of evidence, payers may be looking to an organization such as 
CPIC to provide them with information on patient types at a more granular level. One payer was 
particularly adamant about this concept... 
"I think the consortium should really - and again I don't know if that is the intent 
of what they are trying to do, but I think the consortium should come together and 
say who should be eligible.  At least not just the level of the test itself, but what 
type of patient, what level of risk, age and things like that." Pharmacy Director #7 
- Large Regional Health Plan 
 Payers were probed on the level of influence that the Centers for Medicare and Medicaid 
Services (CMS) would have on how they went about developing policies for these technologies. 
As a starter to this conversation, payers were asked if they would consider doing a type of pilot 
study that CMS has used called "coverage with evidence development". This program allows 
products or services to be covered by CMS only in the context of an approved clinical study. 
These studies are conducted when CMS believes that evidence does not support coverage outside 
of the context of one of these well-designed clinical studies. Payers had mixed reactions to this 
type of program and the implementation with their own data. Some spoke highly of it and the 
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potential for CMS to disseminate their findings to the larger payer audience, “Very likely as a 
pilot we would look at something like that.  We do a lot of pilots in conjunction with CMS." 
Pharmacy Director #2 Regional Health Plan 
Other payers would find the results of such studies from CMS valuable, and instinctively follow 
their lead... 
"I think the learning from that kind of a program probably translates more into the 
potential that at some point down the road, the tests become part of the things like 
system pathways or guidelines…we've used CMS actions in the past that changed 
how we price drugs. I think we could certainly adapt our coverage criteria to if it 
becomes a standard of care..." Pharmacy Director #8 - Regional PBM 
The influence of CMS decisions was an undeniable force in the wider adoption by the payers 
interviewed in this current research. Payers also stressed the impact that a Federal Drug 
Administration (FDA) approval of pharmacogenetic tests and inclusion on FDA product labels 
has on coverage decisions. A FDA label that includes a pharmacogenetic test provides 
substantial evidence to payers that the test provides an additional level of benefit to a (certain) 
patient above the drug itself.  Some indicated that it would be an absolute necessity to have FDA 
labeling to be considered for reimbursement, "I think it's still going to have to be approved by the 
FDA. It has to be part of the product labeling. You don’t see too many other ways around that." 
Pharmacy Director # 5 - PBM w/ medical policy   
The requirement of product labeling seems to be driven, in part, by the demonstration of efficacy 
for products designed for a specific mutation, predominantly somatic.  
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There was skepticism from several payers on the willingness of the pharmaceutical 
industry to support pharmacogenetic testing. The skepticism was based in the view that the 
industry does not realize as much a financial benefit from the sale of drugs in a smaller, more 
directed population. 
"You would think that the pharmaceutical company would come out with it but 
they don't because they want it to be used in everybody and not just specific 
patients." Pharmacy Director #2 - Regional Health Plan 
 Tying in the previous subtheme and role of the FDA, one payer provided an interesting insight 
into future drug development... 
What we're hoping to see…before the drug even is allowed to come to market, is 
suggesting or I guess requiring that manufacturers have some sort of companion 
diagnostic or predictive test that's going to show whether the drug will work on a 
given patient. Then, you could probably price your drug more predictably with the 
expectations of success. I would think they would be in favor of it. Pharmacy 
Director #8 - Regional PBM 
Payers also showed some inherent concern that if a pharmaceutical company were to go about 
developing drugs in much smaller patient populations that they would naturally raise prices to 
compensate for the lost revenue from treating fewer patients. 
"I think they're going to be very cognizant of it as a concern we all have of drugs 
that are targeted. Having drugs available for small target populations notoriously 
meant much more expensive so that the cost savings by targeting the drugs may 
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disappear because the drug prices will go up." Medical Director # 3 - Medical 
group offering insurance 
 To close out the policy development section, payers were asked about the information 
presented in the pre-read concerning the active implementation of preemptive pharmacogenetics, 
the last subtheme. Most payers were pleased that these academic centers had endeavored to 
pursue this implementation as most were positive on the future for this technology.  
"I'd also like to see their data and how it's made a difference, and what specific 
entity, what diseases they treated, and what were the outcomes based on the 
choices that they've made. If you're going to proactively do this, tell me what your 
physicians did with that information. Did they actually change the medication, did 
they alter the dose of the medication, what were the outcomes, and was the patient 
discharged sooner or having a shorter length of stay?" Medical Director #4 - 
Large National Health Plan. 
Payers believe these institutions can potentially provide a great deal of real-world data on 
meaningful outcomes that come from the implementation of such programs.  
 At the conclusion of the interviews, a brief survey was administered using nine likert-
type items on a scale of 1 to 5, 1 = strongly disagree and 5 = strongly agree, to summarize some 
of the major concepts and drivers of payers perspectives on coverage of preemptive 
pharmacogenetics. All but one payer responded to the survey. The full results of this survey are 
found in Table 3 below. 
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   Table 3. Post-interview survey results
Post-interview survey results on five-point Likert-type items (1 = strongly disagree 
to 5 = strongly agree) 
Average score 
(n=13) 
FDA labeling of pharmacogenetic information on approved drugs will impact my coverage 
decision.  
4.6  
Clinician adoption and the endorsement of medical societies for preemptive pharmacogenetic 
testing is/will be an important factor when developing coverage policies.  
4.5  
Pharmacoeconomic data and the demonstration of cost-effectiveness is/will be important in 
determining coverage decisions for preemptive pharmacogenetic testing.  
4.4  
Clinical value is/will be added when clinicians have access to pharmacogenetic data in the 
electronic health record (EHR) at the time of diagnosis and prescribing.  
4.3  
Adoption by CMS and other third-party payers would influence my organization to likewise 
develop coverage policies for preemptive PGx testing. 
4.2  
The clinical validity of the gene-drug pairs determined by CPIC makes pharmacogenetic testing 
more actionable for clinicians  
3.8  
The influence of preemptive pharmacogenetic testing on clinician decision-making is/will be an 
important consideration when evaluating coverage decision.  
3.8  
Preemptive pharmacogenetic testing will provide greater clinical value to the patient and clinician 
by testing hundreds of genetic variants prior to prescribing.  
3.5  
The constructing of reimbursement policies for preemptive pharmacogenetic testing is likely to be 
burdensome.  
3.1  
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5. DISCUSSION 
The examination of the third-party payer’s perspectives on preemptive pharmacogenetics 
provided a diversity of viewpoints on several important topics with which the pharmacogenetic 
research community should be actively following. The proliferation of more objective outcomes 
studies from the use of pharmacogenetic testing is the desire of most payers. There is energy 
from many of these individuals that healthcare and researchers should pursue this, but they cite 
an inability to make decisions hampered by insufficient evidence. The economic perspectives, 
particularly on preemptive pharmacogenetics, focused on budget sustainability from widespread 
organization testing. Not only was the cost from large scale testing a concern, but the difficulty 
in predicting any potential downstream cost benefits was an issue. Although many payers 
speculated that the benefits were a real possibility, the ability to integrate that into coverage 
policies would prove difficult. Third-party payer decision making processes are driven by a 
myriad of forces including the role of both public and private entities. These forces produce an 
interesting layer of influence that should be considered in conjunction with clinical and 
economic data. 
 The stress placed on the development of further evidence of clinical utility was first and 
foremost with many payers. Many payers speculated on the future delivery of healthcare and 
how they thought this technology fit in, but they remained pessimistic on the timeline with which 
preemptive pharmacogenetics would see widespread adoption and utilization. The American 
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Society of Hospital Pharmacists (ASHP) 2016-2020 Pharmacy Forecast found that those 
pharmacists survey believed that 51% thought it very likely or somewhat likely that pharmacists 
in at least half of health systems will be providing treatment recommendations based on 
pharmacogenetics by 2020.
46
 A recurring sentiment was that preemptive testing, or even 
germline testing more broadly, did not provide the payer with the appropriate information to 
make a coverage decision, in contrast to the somatic testing that targets specific mutations within 
the cancer. This is an inherent difference between cancer companion diagnostics and single-gene 
or multi-gene germline pharmacogenetic testing, and their use to the payer. Payers desire the 
"go" or "no-go" indication from a test, but germline testing provides a broader range of data 
covering multiple pharmacogenes and associated drugs in the case of multi-gene testing. The 
actionability of these results do indeed point to instances where the drug being administered 
should be replaced by another drug, in line with companion diagnostics, but in many cases this 
testing leads to the more accurate dosing of pharmaceuticals to avoid adverse events, and thus a 
decision to cover the drug in question or not would be nearly impossible.    
 This cautiousness or pessimism, in part, may stem from a lack of understanding in the 
developing field of germline pharmacogenetics and corresponding relevant evidence. The work 
of CPIC stood out to most payers as a positive step toward improving utilization. Payers found 
CPIC’s work encouraging and similar to NCCN guidelines. Payers continued, however, to refer 
back to the idea that they need information that informs a “yes” or “no” decision to test. This is 
something that the NCCN guidelines contain, likely a reason for their belief and hope that CPIC 
would do the same. Language in the NCCN guideline for gastric cancer strongly recommends 
HER2 testing for those with metastatic disease at time of diagnosis.
47
 Payers believe that 
providing guidance on prescribing and inputting this information in the EHR was positive, but 
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not specific enough to guide policy making. However, the current mission of CPIC is not to 
provide guidance on “when” or “who” should be tested, but rather what providers and patients 
should do with the results of the tests.  
Payers want to see real-world outcomes data from patient populations or randomized 
control trials. When probing payers on the types of data they needed, a mix of responses ranging 
from only clinical trials to retrospective studies came out. Most wanted some sort of prospective 
design where the patient could be followed. The Brixner study described previously that used a 
prospective cohort propensity score matched to a historical cohort could serve as a 
methodological model for researchers outside of a traditional RCT.
21
 Payers control vast 
amounts of patient data and have the opportunity to pilot pharmacogenetic testing rather 
efficiently if needed or desired. However, payers had mix responses when asked if they would 
pursue something of this sort, as CMS did in their “coverage with evidence development” 
program. There was clearly no consensus on proactively moving into these types of studies.  
Prospective studies could answer two questions that payers found to be crucially 
important: what is the benefit of testing and treating over treating and monitoring? And what is 
the number needed to “test” to realize a benefit in one patient? The first question stems from the 
assumption that using a potentially expensive test to dose very inexpensive generics, or having 
the test produce results showing that the patient should be administered a more expensive 
treatment first-line, without consideration of a cheaper generic, would ultimately lead to higher 
health care costs for the system. Advocates of preemptive pharmacogenetics would argue that a 
higher cost pharmaceutical (compared to a drug of lower relative cost) might actually be a cost-
saving pharmaceutical because of its precision with the patient in question, thereby avoiding 
potential adverse events or numerous try and fail strategies with other medications. Large 
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prospective studies would provide the evidence needed to answer this question and the objective 
outcomes payers desire. 
Answering the number needed to “test” question would provide an objective figure with 
which to evaluate specific pharmacogenetic tests. This type of data is particularly important for 
preemptive and germline pharmacogenetics because part of the benefit from this technology 
comes from avoidance of adverse events and potential re-hospitalizations. According to the 
interviewees, both physicians and payers find value in this type of information. Member 
hospitals of the PGRN community are implementing preemptive pharmacogenetic programs and 
have the opportunity to present information that could help answer some of these pressing 
questions. Current implementations of pharmacogenetics in clinical practice might be providing 
enough data to begin calculating NNT's within their patient populations.
1
 Recent work by Tonk 
et al., describes some appropriate methodologies to evaluate measures of population impact from 
pharmacogenetic tests including the NNT, as well as a population attributable fraction (PAF).
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The PAF indicates what proportion of adverse events would be eliminated if patients carrying a 
variant received a different treatment. These types of data provide strong assessments of clinical 
validity by predicting adverse events and its impact on broader population health.
 
The conversation around cost with the payers was consistent and focused on the cost of 
testing large swaths of the population, the associated upfront cost, and the unpredictability of 
downstream cost savings. Once again, payers used the cancer companion diagnostics to frame 
their responses. It was an easy decision for payers to spend several hundred or a few thousand 
dollars on a test for a drug that cost upwards of six figures, but outside of that it became much 
more tenuous. Payers indicated little focus on the actual downstream costs associated with 
preventing adverse events and re-hospitalizations. The variability in how payers evaluate 
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downstream costs is likely driven, in large part, by the type of organizations. Many traditional 
insurers indicated a one year time-frame for evaluations of costs, utilizations, and benefits. 
Recognizing how preemptive pharmacogenetics postulates its benefit, this time-frame of 
economic evaluation is unlikely to lend itself to positive conclusions. Those from more 
integrated systems, meaning some higher level of coordination among providers and payers, 
appeared more willing to move toward preemptive testing.  
Stronger assessments of this information might facilitate the adoption of 
pharmacogenetics into those with value-based purchasing structures looking to avoid ineffective 
care.
4
 Concerns with when a patient and physician would actually use the data, and what cost 
offsets might be realized, was another reason for caution as payers evaluated this use. Most of 
the products or interventions presented to payers for evaluation are designed to address a 
particular disease state or certain condition, and thus can be prescribed in a treatment plan after 
an official diagnosis. Preemptive pharmacogenetics demonstrates its value prior to diagnosing 
and prescribing, but sometimes with an unknown time frame for utilization, and thus presents a 
challenging assessment of cost tradeoffs. Reactive pharmacogenetics alleviates the concern of 
paying for a test whose results might not be used for years, but the reach of most reactive tests is 
usually limited to the single pharmacogene in question for the treatment being prescribed and 
will likely be not be cost-effective as the price of all types of testing continues to drop. Relling 
and Evans note this coming crossroad when a decision must be made between a test that is 
ordered for one gene because of immediate actionability on a diagnosis and a test for genes that 
includes the former, but also provides genetic information for future diagnoses.
2 
To probe the topic of large upfront costs further the payers were asked to consider if they 
would stratify beneficiaries based on age or number of co-morbidities. This was also met with 
51 
 
variable response and hesitancy due to potential ethical or legal issues. However, the use of pilot 
programs as discussed previously might provide useful prospective information on what types of 
patient cohorts are benefiting the most from preemptive pharmacogenetic testing. If payers 
remain apprehensive to the widespread adoption, a strategy such as this could prove useful to 
gradually increasing the number of patients with pharmacogenetic data loaded into their EHR. 
However, this could be limited by the type of clinical decision support system employed at the 
site of care and subsequent usability of the data.  
The conversation that implicitly developed and was suggested by several payers 
concerning the adoption of pharmacogenetic as a preventive health technology endorsed by the 
U.S. Preventive Services Task Force (USPSTF) was particularly interesting. Some payers 
suggested that achieving coverage through this course of action was more appropriate for this 
type of technology, although citing the stringent approval process. However, this is not 
completely unrealistic. The USPSTF is an independent body that was convened by the Agency 
for Healthcare Research and Quality.
49
 Recommendations are frequently met with opposition 
from various clinical groups due to impacts on current practice. For example, a series of 
exchanges between editors and readers of the journal Radiology in 2010 demonstrated strong 
opinions and dissent on the change in recommendations of appropriate age for regular breast 
cancer screenings.
50
 It is likely that something such as preemptive pharmacogenetic testing 
would be met with a similar form of resistance.  
The number of preventive services covered expanded with the implementation of the 
Affordable Care Act in 2010. Some of these services are one-off screenings but many may 
require recurring screenings to work effectively. Multi-gene pharmacogenetic testing could 
potentially provide a screening with utilization for an indefinite time period, and thus not require 
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any re-screening. However, it is likely that even the largest multi-gene pharmacogenetic test will 
at some point in the future require expansion as more gene-drug relationships are discovered year 
by year. Whole genome sequencing would ensure the complete mapping of relevant 
pharmacogenes, but the current widespread implementation of this would be economically 
untenable.  
The impact of CMS was briefly mentioned previously with regards to the “coverage with 
evidence development” but it is worth noting that payers do stay abreast of policy decisions from 
CMS and will make many of their own decisions in line with them. Payers also mentioned the 
importance of pharmacogenetic tests being included on the FDA label. When considering the 
functionality of a preemptive multi-gene pharmacogenetic test for germline mutations, making a 
coverage decision based on FDA labeling will likely be a more nuanced processed. Almost 200 
drug products driven by known pharmacogenes already contain pharmacogenetic data as part of 
their approved FDA label. Many of these labels, however, do not require pharmacogenetic 
testing for approval as we have seen in oncology drugs targeting a specific mutation. Again, this 
demonstrates the payer difficulty in dealing with the disconnect between the obvious yes or no 
decision and the presentation of pharmacogenetic data in the label as it applies to dosage and 
administration, precautions, use in specific populations, and adverse reactions. The inclusion of 
pharmacogenetic data on the majority of FDA labels, outside of the oncology space, does not 
provide payers with the appropriate level of evidence to make a similar decision. Exceptions 
include the drug abacavir, which can lead to a fatal hypersensitivity reaction in some patients, 
specifically mentions screening for the HLA-B*5701 allele before dose initiation.
33
 Other 
medications such as clopidogrel, which has strong clinical support for diminished antiplatelet 
53 
 
effect in some patients, contains a boxed warning but does not specifically require testing prior to 
administration.  
The evolution of policy development for pharmacogenetics is going to be an ongoing and 
fluid process, requiring tremendous input from sources both private and public. Truly widespread 
adoption of pharmacogenetic testing will require the work of academic researchers in 
communities such as PGRN and CPIC to provide that next level of evidence to guide policy 
decision making.  
 
Future directions 
 The findings from this study provide the pharmacogenetic research community with 
several avenues for potential research opportunities. A greater number of prospective real-world 
population studies testing the impact of preemptive pharmacogenetic testing on measurable 
outcomes will provide the strongest evidence to facilitate greater adoption. This approach must 
also include an assessment of those “downstream” costs that payers referenced several times. 
This type of analysis is not top of mind for many of these decision makers, but as we move more 
towards value based healthcare, the importance of this type of data will become ever more 
relevant. Wade et al. stress the importance and role that genomic programs have in developing 
value-based and patient-centered healthcare.
7
 Several aforementioned methodologies have been 
described to evaluate pharmacogenetic tests in a manner that produces data that will be of greater 
interest to payers and policy decision makers, and should be pursued accordingly. Detailed and 
speculative economic modeling of the pharmacogenetic tests can provide an assessment of 
potential costs that could potentially be avoided. The granular identification of these costs can 
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then be applied to real-world studies improving the applicability and dissemination among 
various care settings. 
Several opportunities exist to explore pharmacogenetics role in future health policy. 
Studying the potential role of the U.S. Preventive Services Task Force would serve as evidence 
for broad implementation of preemptive pharmacogenetics as a population health policy. Also, 
the shift towards value-based reimbursement structures might facilitate the adoption of more 
preventive measures and increase the reach of preemptive pharmacogenetics. 
 
Limitations  
 The respondent self-selection to participate in the screener survey may suggest that they 
are more familiar with pharmacogenetics than the average third-party payer, or that their interest 
might bias their responses in some way. Although this bias would be impossible to ascertain, no 
biases were identified between those respondents who agreed to participate in the interview and 
those that did not when comparing responses on the screener survey. Comparability of data may 
have been reduced due to the different wording and sequencing of each interview. However, 
richness is gained through this by allowing each interview to gain its own coherence. Qualitative 
data always come with a question of the level of truth. In this case respondents had no incentive 
to provide responses that were anything other than accurate. It would be difficult to imagine a 
scenario in which the respondent personally benefited from providing untruthful data. 
Conclusion 
 Third-party payer opinions of preemptive pharmacogenetic testing indicate a cautious 
optimism. Concern over the lack of objective outcomes available, an inability to assess economic 
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benefits, and the potential high costs from widespread testing are the central reasons for this 
caution. Payers are, however, encouraged by the efforts of organizations such as CPIC that are 
making the data that is available more actionable and the consortiums that are implementing 
pharmacogenetic interventions in real-world populations. Expanding reimbursement and 
exposure of pharmacogenetics to the medical professions should facilitate greater physician 
adoption and provide further opportunities to study associated outcomes in meaningful ways. 
This study should be viewed as a call to advocates in the pharmacogenetic research community, 
both clinically and socially, to continue the pursuit of work directed at addressing the needs 
described within.  
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1 PharmGKB: www.pharmgkb.org 
Clinical Annotation Levels of Evidence
1
  
1A Annotation for a variant-drug combination in a CPIC or medical society-endorsed 
PGx guideline, or implemented at a PGRN site or in another major health system.  
1B Annotation for a variant-drug combination where the preponderance of evidence 
shows an association. The association must be replicated in more than one cohort 
with significant p-values, and preferably will have a strong effect size. 
2A Annotation for a variant-drug combination that qualifies for level 2B where the 
variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. 
The variants in level 2A are in known pharmacogenes, so functional significance is 
more likely. 
2B Annotation for a variant-drug combination with moderate evidence of an association. 
The association must be replicated but there may be some studies that do not show 
statistical significance, and/or the effect size may be small. 
3 Annotation for a variant-drug combination based on a single significant (not yet 
replicated) or annotation for a variant-drug combination evaluated in multiple studies 
but lacking clear evidence of an association. 
4 Annotation based on a case report, non-significant study or in vitro, molecular or 
functional assay evidence only. 
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Good Morning, 
  
I hope this email finds you well. I have a research opportunity I think you would be interested in. 
  
The research will be conducted in two parts, between the dates of April 27 - May 18.  It will 
cover preemptive pharmacogenetic testing. 
  
This portion of the research includes a brief online survey that will take approximately 5 minutes 
to complete. This research is being conducted for academic purposes so we will be asking some 
questions to ensure alignment with the research objectives. 
 
Please follow the link below to begin the survey. 
 
<<<qualtrics link>>> 
 
Thank you. 
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Thank you for your participation in this research. You will be required to answer all 
questions but you may withdraw at any time. Your name and institution will always 
remain confidential.  
By completing the survey/interview you consent to participate in the study. 
1. Are you at least 18 years of age or older? 
o Yes 
o No (not eligible to continue) 
2. Are you a...? 
o Medical director 
o Pharmacy director 
o Other, please specify _________ 
3. Approximately how many lives are covered on your plan? 
 
4. What percent of your covered lives fall into each plan type? 
 
 
5. What is the average length of time a beneficiary stays with your organization? 
6. Does your organization have an official health technology committee? 
o Yes 
o No 
o Unsure 
7. If answered yes to Q7....have you served on this committee? 
o Yes 
o No 
 
8. How would you rate your organization relative to other health plans regarding 
adoption/coverage of new health technologies? 
 
 
9. Please rate your level of familiarity with all types of pharmacogenetic testing. 
 
 % 
a. Commercial PPO/POS  
b. Commercial HMO/IPA  
c. Medicaid (any)  
d. Medicare   
f. Other, please specify___________  
 SUM = 100% 
Laggard 
Late majority 
adopter 
Early majority 
adopter 
Early adopter Innovator 
o  o  o  o  o  
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Pharmacogenetic 
testing 
 Somatic pharmacogenetics - Identification of acquired genomic 
variants that influence response to drug , this type of 
pharmacogenetics is mostly relevant in malignancies to guide the 
choice of anticancer therapy 
 Germline pharmacogenetics- Identification of inherited genomic 
variants that influence alterations in a drug's pharmacokinetic and 
pharmacodynamics properties 
Not at all 
familiar 
Slightly 
familiar 
Somewhat 
familiar 
Moderately 
familiar 
Very 
familiar 
o  o  o  o  o  
 
 
10. Do you currently cover any pharmacogenetic tests or have you reviewed any in the past? 
o Yes 
o No 
11. List any tests you know of that are currently covered: _________________________ 
 
12. How would you rate your organization relative to other health plans regarding your level 
of management of pharmacogenetic testing? 
 
Not at all 
managed 
Slightly managed 
Somewhat 
managed 
Moderately 
managed 
Highly managed 
o  o  o  o  o  
 
 
13. Please rate your level of familiarity with preemptive pharmacogenetic testing. 
 
Preemptive 
multi-gene 
pharmacogene
tic testing 
 
 Broad screening of multiple pharmacogenes 
 Pharmacologic effects of most medications are determined by multiple 
pharmacogene products 
 Test results are available in the medical record as a pre-prescription 
patient characteristic (independent of whether a patient is going to 
receive a high-risk medicine) 
 Array-based preemptive testing can include a large number of relevant 
pharmacogenes that cover most  drugs that have a pharmacogenetic 
implication for dosing 
 
Not at all 
familiar 
Slightly 
familiar 
Somewhat 
familiar 
Moderately 
familiar 
Very 
familiar 
o  o  o  o  o  
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14. Has preemptive pharmacogenetic testing been discussed at any of your P&T meetings in 
the last two years? 
o Yes 
o No 
o Don’t know 
 
15. Does your organization have a formal approach to covering preemptive pharmacogenetic 
testing? 
o Yes 
o No, but in the process of putting one together and will have one in the next 
few years 
o No, and no plans for the future 
 
16. Are you aware of the clinical setting implementations of any preemptive 
pharmacogenetic programs? 
o Yes 
o No 
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Good Morning, 
  
Thank you for participating in the first portion of the academic research on Preemptive 
Pharmacogenetic Testing.  I am writing to invite you to participate in Part 2 of the research. 
 
This portion of the research includes a 30-45 minute telephone discussion with Nick Keeling to 
be conducted sometime between Monday, May 23 and Friday June 3.  Please contact 
<<<project coordinator>>> at (XXX) XXX-XXX ext. XXX OR email <<<project 
coordinator>>> at <<<email address>>> to schedule.   
  
Please be certain to provide  <<<project coordinator>>>  with the telephone number we should 
call you at for your interview. 
 
As a reminder, this study has been reviewed by The University of Mississippi’s Institutional 
Review Board (IRB).  If you have any questions, concerns, or reports regarding your rights as a 
participant of research, please contact the IRB at (662) 915-7482 or irb@olemiss.edu. 
 
Thank you. 
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Thank you for agreeing to participate in this study. My name is Nick Keeling and I am 
conducting interviews with payer decision-makers regarding their perspectives on 
pharmacogenetic testing, with an emphasis on germline, preemptive testing, and the coverage 
policies associated with this technology. 
I also want to inform you that I’ll be recording this interview so that I don’t waste your time 
taking notes. Your name and the name of your organization will remain confidential. We expect 
this interview to take approximately 45 minutes. You may withdraw from the interview at any 
time. Do you have any questions for me before we begin? 
Please refer to the pre-read information that was provided to you in the invitation email. 
Clinical 
Pharmacogenetics 
Implementation 
Consortium (CPIC)  
 Assesses clinical validity (the ability of the test to differentiate between 
responders and nonresponders, or to identify patients who are at risk for 
adverse drug-reactions)  of gene-drug pairs to determine those that are 
clinically actionable 
 These guidelines adhere to the Institute of Medicine's Standards for 
Developing Trustworthy Clinical Practice Guidelines 
 CPIC recommendations are in four levels: A, B, C, D 
o A - Genetic information should be used to change prescribing of 
affected drug 
o B - Genetic information could be used to change prescribing of the 
affected drug because alternative therapies/dosing are extremely 
Pharmacogenetic 
testing  
Broad definition:  Pharmacogenetics is the study of how genes affect a person’s 
response to drugs. 
 Somatic Pharmacogenetics – The study of how acquired genomic variants 
influence response to drug , this type of pharmacogenetics is mostly 
relevant in malignancies to guide the choice of anticancer therapy (typically 
a companion diagnostic) 
 Germline Pharmacogenetics - The study of how inherited genomic 
variants influence alterations in a drug's pharmacokinetic and 
pharmacodynamics properties 
Reactive single-gene 
pharmacogenetic 
testing 
 Single-gene test ordered one at a time when patient is likely to need a 
pharmacogenetically high-risk drug 
 Adopted into clinical practice first because of strong monogenic gene-drug 
associations 
 Decision based on likelihood that a high-risk drug will be prescribed for a 
patient or group of patients 
 Increased likelihood that the genetic test result is applied by the clinician 
because the prescribing decision is linked to performance of genetic test 
Preemptive multi-
gene 
pharmacogenetic 
testing 
 Broad screening of multiple pharmacogenes 
 Pharmacologic effects of most medications are determined by multiple 
pharmacogene products 
 Test results are available in the medical record as a pre-prescription patient 
characteristic (independent of whether a patient is going to receive a high-
risk medicine) 
 Array-based preemptive testing can include a large number of relevant 
pharmacogenes that cover most  drugs that have a pharmacogenetic 
implication for dosing 
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likely to be as effective and as safe as non-genetically based dosing 
o C - There are published studies at varying levels of evidence, some 
with mechanistic rationale, but no prescribing actions are 
recommended because (a) dosing based on genetics convincingly 
makes no difference or (b) alternatives are unclear, possibly less 
effective, more toxic, or otherwise impractical. 
o D - There are few published studies, clinical actions are unclear, 
little mechanistic basis, mostly weak evidence, or substantial 
conflicting data. If the genes are not widely tested for clinically, 
evaluations are not needed. 
 There are currently 41 gene-drug pairs that are listed level A. 
 Gene-drug pairs are considered for several reasons: 
o Actionable in professional society guideline 
o Nominated by CPIC member or outside advocate like FDA 
o PharmGKB annotation level 1A, 1B, 2A, 2B 
 PharmGKB is a pharmacogenomics knowledge resource 
managed by Stanford University that focuses on genotype-
based summaries of the association between a drug and 
the gene variant 
o Mentioned in professional society guidelines but not actionable 
Example of Clinical 
Decision Support 
from preemptive 
test  
CYP2C19 - 
citalopram 
 
(https://www.pharmg
kb.org/guideline/PA1
66127638) 
CDS Alert trigger 
Condition 
CDS 
Context, 
Relative 
to 
Genetic 
Testing 
CDS Alert Text (specific wording of the alert 
text may differ among programs) 
No CYP2C19 test on 
file and citalopram 
ordered 
Pre-test CYP2C19 genetic status may be predictive of an 
adverse reaction or poor response to this 
medication. A CYP2C19 genotype does not 
appear to have been ordered for this patient. Use 
of an alternative drug or dose may be 
recommended. Please consult a clinical 
pharmacist for more information. 
CYP2C19 UM and 
citalopram ordered 
Post-test This patient is predicted to be a CYP2C19 
ultrarapid metabolizer and may be at an 
increased risk of a poor response due to low 
plasma concentrations of citalopram. Consider 
selecting an alternative SSRI not extensively 
metabolized by CYP2C19. Please consult a 
clinical pharmacist for more information. 
CYP2C19 EM  or 
IM and citalopram 
ordered 
Post-test No CDS 
CYP2C19 PM and 
citalopram ordered 
Post-test This patient is predicted to be a CYP2C19 poor 
metabolizer and may be at an increased risk of 
an adverse reaction due to elevated citalopram 
plasma concentrations. Consider a 50% 
reduction of the recommended starting dose and 
titrate to response or select alternative drug not 
predominantly metabolized by CYP2C19. Please 
consult a clinical pharmacist for more 
information.   
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Implementation of 
preemptive 
pharmacogenetics in 
healthcare settings 
 Pharmacogenomics Research Network (PGRN) formed the Translational 
Pharmacogenetic Program (TPP)  
o Implement routine, pharmacogenetically based prescribing within 
diverse health-care systems 
 Vanderbilt University Medical Center (VUMC), Mayo Clinic, Mount Sinai 
Medical Center, St. Jude Children's Research Hospital, University of 
Florida, and the University of Chicago have all implemented programs using 
a preemptive pharmacogenetic approach 
 VUMC PREDICT program - 5 year retrospective study of 52,942 medical 
home patients found that 54% of patients were exposed to at least one 
medication with a known pharmacogenetic response. 383 adverse events 
were hypothetically avoided. 
 St. Jude Children's Research Hospital - currently 7  genes coupled with 
17 high-risk drugs with upwards of 55 corresponding clinical decision 
support prescribing guidelines. Approximately 3,500 patients enrolled to 
date 
 The University of Chicago - "1,200 Patients Project" - As of 2014, 812 
patients enrolled and 608 genotyped. Developed a genomic prescribing 
system using red (high-risk), yellow(caution), and green (favorable) lights. 
At 268 clinic encounters, 86% of physicians accessed the GPS with 100%, 
72%, and 20% click frequencies for the respective signals 
 Other preemptive pharmacogenetic implementations 
o Inova Health System MediMapTM PGx Test offered to all newborns 
currently and expanding to all ages soon 
o Northshore University Health System (teaching afflation) 
 Currently testing pharmacogenes corresponding to13 
drugs 
 
Introductory questions: 
1. Please briefly describe to me your decision making role at your organization. Does your 
organization have a medication technology/tech assessment committee?  How often do you 
meet?  
2. What is your organization's approach to the movement of precision medicine? Is this 
something that is discussed regularly?  
3. What are your current perceptions of the market for pharmacogenetic testing? 
a. How would you define value for a pharmacogenetic test?  
4. How does the evaluation of a pharmacogenetic test differ from other types of health 
technology? Or does it? 
5. How often does your medical technology committee evaluate a new pharmacogenetic test? 
6. What evidence does your medical technology committee consider when evaluating a 
pharmacogenetic test? 
a. What facilitators and barriers are there to covering pharmacogenetic tests? 
7. What is the budget impact of this type of technology? Explain to me if your organization has 
experienced any budget / financial issues with paying for pharmacogenetic testing. 
a. Do you currently contract with a major laboratory for these types of testing? 
(LabCorp, Quest, etc) 
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Clinical Validity and Utility of Pharmacogenetic Testing 
11. Were you aware of the work from CPIC prior to this interview? What impact does this have 
on your assessment of the clinical validity of pharmacogenetic testing? 
12. What type of trial use or data would be most helpful in the decision-making process for your 
med tech committee? Is the RCT still the "gold standard"?  
a. Probe: Issues with the RCT (affects outliers more and thus incremental benefit appears 
small in large samples, ethical issues with knowingly giving drug to a non-responder) 
b. Probe: Retrospective studies of before and after preemptive implementation? 
13. How do you define clinical utility for pharmacogenetic tests?  
a. Probe: Ability to prevent adverse events more quickly, prescribing the right drug the first 
time. 
14. In the absence of an RCT, what other types of evidence would you consider most influential 
in policy development?  
a. Probe: Better outcomes, change in prescribing, cost-effectiveness, society guidelines? 
b. Would you consider CPIC guidelines evidence of clinical utility?  
15. What impact could preemptive genetic testing have on patient outcomes? 
a. Is this different than the reactive/point-of-care pharmacogenetic testing method? 
 
 
Perception of Value and Cost Factors Associated with Pharmacogenetic Tests 
 
16. Have you reviewed any pharmacoeconomic data on pharmacogenetic testing?  
17. What economic impact do you see preemptive pharmacogenetic testing having on your plan? 
Probe: A well-known pharmacogenetic assay that tests for 231 genes related to drug 
metabolism is approximately double the cost of a single gene test.  
18. Do you believe preemptive pharmacogenetic testing is a preventive technology? 
a. Discuss your thoughts on the role of preemptive pharmacogenetic testing value-based 
payment environment. 
b. What economic drawbacks can you see from this? 
19. Are you familiar with the prices for any pharmacogenetic tests that are currently available, 
either multi-gene or single-gene assays? 
a. Probe: Provide info that multi-gene assay is $560 vs. single-gene of $225 
b. Ask if familiar: Is there a price where you would consider adopting preemptive 
pharmacogenetic testing more readily? Or does price even matter (i.e. more clinical)? 
 
Coverage and reimbursement issues for pharmacogenetic testing  
 
20. Does your organization approach coverage policy for somatic pharmacogenetic testing 
(companion diagnostics) and germline pharmacogenetic testing (pharmacokinetics) 
differently? What are the factors?  
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a. Cost of associated drug? Severity of the underlying disease for pharmacogenetic-guided 
treatment? Potential severity of the adverse effect? 
21. Discuss what the coverage and reimbursement decision-making process for a preemptive 
pharmacogenetic test would look like. 
a. How would the potential time gap between administering a preemptive pharmacogenetic 
test and clinical utility have an impact on coverage policy? 
b. Discuss your thoughts on restricting access to sub-sets of beneficiaries that might realize 
positive outcomes sooner than others from pharmacogenetic testing.  
c. Is determining coverage of preemptive testing more complex than reactive? 
d. Is there a certain number of actionable gene-drug pairs or disease areas that need to be 
covered by the test to make in reimbursable? 
22. What is the average amount of time a beneficiary spends with your plan? 
a. What implications might the time-gap have on policy development?  
23.  Are you familiar with the CMS program called "coverage with evidence development 
program" to assess the clinical utility of the test in practice? 
a. Has your organization ever addressed this approach or would this be considered? 
24. Does the utilization of preemptive pharmacogenetics in practice (Vanderbilt, St. Jude, U of 
Chicago, Inova Health, etc) have an impact on your decision to cover or not? 
 
That is all the questions I have for you today. Would you like to add anything to our discussion 
on preemptive pharmacogenetic testing or pharmacogenetic testing more generally? 
If you have any further questions about the study feel free to reach to me. My email is 
njkeelin@go.olemiss.edu. Thank you for your time. 
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Please indicate your level of agreement or disagreement with the following statements on the 
following scale. 
Strongly 
disagree 
Disagree 
Neither agree or 
disagree 
Agree Strongly agree 
o  o  o  o  o  
 
1. The clinical validity of the gene-drug pairs determined by the Clinical Pharmacogenetic 
Implementation Consortium (CPIC™) makes pharmacogenetic testing more actionable 
for clinicians. 
2. Clinical value is/will be added when clinicians have access to pharmacogenetic data in 
the electronic health record (EHR) at the time of diagnosis and prescribing. 
3. The influence of preemptive pharmacogenetic testing on clinician decision-making is/will 
be an important consideration when evaluating coverage decision. 
4. Preemptive pharmacogenetic testing will provide greater clinical value to the patient and 
clinician by testing hundreds of genetic variants prior to prescribing. 
5. Pharmacoeconomic data and demonstration of cost-effectiveness is/will be important in 
determining coverage decisions for pharmacogenetic testing. 
6. The constructing of reimbursement policies for preemptive pharmacogenetic testing may 
be burdensome. 
7. Clinician adoption and the endorsement of medical societies for preemptive 
pharmacogenetic testing is/will be an important factor when developing coverage 
policies. 
8. FDA labeling of pharmacogenetic information on approved drugs will impact my 
coverage decision. 
9. Adoption by CMS and other third-party payers would influence my organization to 
likewise develop coverage policies for preemptive pharmacogenetic testing.
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